220 related articles for article (PubMed ID: 19190907)
41. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
42. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines.
Kudryashov V; Kim HM; Ragupathi G; Danishefsky SJ; Livingston PO; Lloyd KO
Cancer Immunol Immunother; 1998 Feb; 45(6):281-6. PubMed ID: 9490197
[TBL] [Abstract][Full Text] [Related]
44. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
Front Immunol; 2019; 10():2497. PubMed ID: 31708925
[No Abstract] [Full Text] [Related]
45. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
Longenecker BM; Reddish M; Koganty R; MacLean GD
Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
[TBL] [Abstract][Full Text] [Related]
46. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
47. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
[TBL] [Abstract][Full Text] [Related]
48. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen.
MacLean GD; Bowen-Yacyshyn MB; Samuel J; Meikle A; Stuart G; Nation J; Poppema S; Jerry M; Koganty R; Wong T
J Immunother (1991); 1992 May; 11(4):292-305. PubMed ID: 1599915
[TBL] [Abstract][Full Text] [Related]
49. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
Neelapu SS; Baskar S; Kwak LW
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
[TBL] [Abstract][Full Text] [Related]
50. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.
Zhang S; Graeber LA; Helling F; Ragupathi G; Adluri S; Lloyd KO; Livingston PO
Cancer Res; 1996 Jul; 56(14):3315-9. PubMed ID: 8764127
[TBL] [Abstract][Full Text] [Related]
51. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
[TBL] [Abstract][Full Text] [Related]
52. Immune response of the female rat genital tract after oral and local immunization with keyhole limpet hemocyanin conjugated to the cholera toxin B subunit.
Menge AC; Michalek SM; Russell MW; Mestecky J
Infect Immun; 1993 May; 61(5):2162-71. PubMed ID: 8478106
[TBL] [Abstract][Full Text] [Related]
53. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
54. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
[TBL] [Abstract][Full Text] [Related]
55. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
[TBL] [Abstract][Full Text] [Related]
56. Carbohydrate vaccines as immunotherapy for cancer.
Slovin SF; Keding SJ; Ragupathi G
Immunol Cell Biol; 2005 Aug; 83(4):418-28. PubMed ID: 16033538
[TBL] [Abstract][Full Text] [Related]
57. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
58. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm.
Ragupathi G; Koganty RR; Qiu D; Lloyd KO; Livingston PO
Glycoconj J; 1998 Mar; 15(3):217-21. PubMed ID: 9579798
[TBL] [Abstract][Full Text] [Related]
59. The known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines.
Hong F; Xiao W; Ragupathi G; Lau CB; Leung PC; Yeung KS; George C; Cassileth B; Kennelly E; Livingston PO
Planta Med; 2011 May; 77(8):817-24. PubMed ID: 21128203
[TBL] [Abstract][Full Text] [Related]
60. Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells.
Kircheis R; Siegl P; Grunt S; Halanek N; Loibner H; Mudde GC; Nechansky A
Cancer Immunol Immunother; 2007 Jun; 56(6):863-73. PubMed ID: 17009044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]